Sit Investment Associates Inc. Sells 10,675 Shares of Moderna, Inc. (NASDAQ:MRNA)

Sit Investment Associates Inc. lowered its holdings in Moderna, Inc. (NASDAQ:MRNA - Free Report) by 59.0% in the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 7,409 shares of the company's stock after selling 10,675 shares during the quarter. Sit Investment Associates Inc.'s holdings in Moderna were worth $308,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in MRNA. Grantham Mayo Van Otterloo & Co. LLC bought a new stake in shares of Moderna during the 4th quarter valued at about $22,778,000. Pilgrim Partners Asia Pte Ltd bought a new stake in Moderna during the 4th quarter valued at approximately $67,000. Resona Asset Management Co. Ltd. purchased a new position in shares of Moderna during the 4th quarter worth approximately $3,920,000. Prudential PLC raised its position in shares of Moderna by 122.5% in the 4th quarter. Prudential PLC now owns 12,210 shares of the company's stock worth $508,000 after acquiring an additional 6,722 shares in the last quarter. Finally, Annis Gardner Whiting Capital Advisors LLC lifted its stake in shares of Moderna by 15.4% in the 4th quarter. Annis Gardner Whiting Capital Advisors LLC now owns 5,441 shares of the company's stock valued at $226,000 after purchasing an additional 725 shares during the period. 75.33% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on the company. UBS Group reduced their price target on Moderna from $96.00 to $78.00 and set a "buy" rating on the stock in a research note on Wednesday, February 19th. The Goldman Sachs Group downgraded shares of Moderna from a "buy" rating to a "neutral" rating and reduced their target price for the stock from $99.00 to $51.00 in a research report on Wednesday, January 29th. Argus lowered shares of Moderna from a "buy" rating to a "hold" rating in a research note on Wednesday, December 18th. Berenberg Bank boosted their price objective on shares of Moderna from $33.00 to $42.00 and gave the stock a "hold" rating in a research note on Thursday, January 16th. Finally, Barclays downgraded shares of Moderna from an "overweight" rating to an "equal weight" rating and decreased their target price for the company from $111.00 to $45.00 in a research note on Tuesday, February 18th. Four analysts have rated the stock with a sell rating, sixteen have issued a hold rating, three have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Hold" and a consensus price target of $58.70.

Remove Ads

Moderna Stock Performance

Shares of MRNA stock traded up $1.70 during trading hours on Friday, reaching $26.20. The company had a trading volume of 10,999,018 shares, compared to its average volume of 7,181,061. The business has a fifty day moving average price of $31.56 and a 200-day moving average price of $41.01. Moderna, Inc. has a one year low of $23.15 and a one year high of $170.47. The firm has a market cap of $10.13 billion, a PE ratio of -2.82 and a beta of 2.23.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.